The current study aimed at identifying the role of seizure types and related clinical features in differentiation between neurometabolic disorders and other causes of seizure.
Introduction
Inborn Error of metabolism (IEM) is a group of disorders in which genetic abnormalities at the cellular level result in the lack or dysfunction of specific enzymes, cofactors, or transporters required for fatty acid, amino acid, or carbohydrate metabolism (1) . Some IEM disorders affecting the nervous system are considered as neurometabolic disorders. Brain is susceptible to damage in such situations (2) . Seizure is a common manifestation in neurometabolic disorders and may be considered as a presenting symptom. Epilepsy is not rare in the general population (seizures occur in one per 1000 live births) (3) . Seizure is a common symptom of metabolic diseases reported in about 200 different IEM disorders (3); however, there are limited data on the certain seizure patterns in patients with metabolic disorders (1, 2, (4) (5) (6) . Therefore, some specific features are reported in seizures along with neurometabolic disorders (7) .
Early onset seizures and refractory seizures accompanied by developmental disabilities are commonly observed in IEM disorders (8) .
Regarding seizure, clinical findings are often nonspecific (9, 10) , and high index of suspicion is needed to consider neurometabolic disturbances. 
Materials & Methods
The current case-control study aimed at comparing Finally, the characteristics were compared between the two groups. The study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran. All patients were included in the current study with parental informed consent.
Statistical analysis
Continuous data were expressed as mean ± standard deviation and categorical data as frequency and percentage. In order to compare the characteristics and outcomes between the two groups, independent samples t-test, the Mann Whitney and Chi-squared tests were applied and the exact P-values were calculated whenever needed. The significance level was set at 0.05 and SPSS version 21 was used for data analysis.
Results
Of the visited 213 patients with neurometabolic disorders, 55% (n=120) had seizure disorder (case group). Pattern of seizure and related clinical findings in the case group were compared with those of the 120 cases with seizure secondary to other causes.
Mean age of the patients at the time of evaluation was significantly different between the case and control groups (39.86± 47.43 vs. 73.76± 51.18 months; P=0.001). There were 56 female and 64 male patients in the case group and 60 female and 60 male patients in the control group, indicating an insignificant difference between the groups in this regard (P=0.698). Age at the onset of seizures was significantly lower in the case group than the control group (13.20 ± 21.40 vs. 40.90 ± 36.50 months; P <0.001), data are shown in Table 1 .
Distribution of the types of seizure was significantly different between the two groups (P <0.001); tonic and myoclonic, infantile spasm, and mixed-type seizures were more common in the case group, while atonic, absence, partial, and GTC seizures were more frequently observed in the control group, data are shown in Table 3 Brain MRI Valuable findings were observed in 62.5% of the case vs 21.7% of the ones in the control groups, which were significantly different (P=0.0001). In patients with metabolic disorders, white matter involvement was seen in 23 and brain atrophy in 50 cases. In six patients brain atrophy was associated with basal ganglia involvement , and two cases had white matter involvement along with basal ganglia anomaly. Infarct was observed in two patients ,too. (Figure 1 ). Previous studies revealed that seizure is a common presentation of neurometabolic disorders to such an extent that 40%-90% of patients with such problems experience seizure (2, 11) . Several studies indicated that some types of seizure are more common in neurometabolic disorders; e g, infantile spasm and myoclonic seizure (2, 12) .
In the current study, seizure started earlier in patients with neurometabolic disorders than the subjects in the control group (mean age: 39.86 vs. 73.76 months), which was in accordance with previous studies that reported ≤12 months old (14, 15) .
The presence of some of these findings helped to diagnose some specific metabolic disorders; for example, cherry-red spot was common in most patients with GM2 gangliosidosis or skin lesion was a diagnostic key for biotinidase deficiency (16, 17) . Developmental regression is an important diagnostic key for metabolic diseases when patients present with seizure, which is less expected concomitant with seizures due to other causes (10) .
In the current study results, the percentage of parental consanguinity in patients with neurometabolic disorders was significantly higher than that of controls (82.5% vs. 22.5%), which was in accordance with the findings of Sarar and Masry that reported the frequency of neurometabolic disorders in 75% and 77.1% of patients with parental consanguinity, respectively (1, 4) ; it can be explained by the fact that neurometabolic disorders are among autosomal recessive disorders.
Family history of seizure disorders was positive in approximately one-third of the current study patients in both groups, and there was no significant difference between them in this respect.
Previous studies revealed positive family history in 22%-33% of patients with neurometabolic disorders (1, 12) , which was in accordance with the current study results, but those studies did not 
